COMP <GO>
ORGO vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
Organogenesis Holdings Inc. (Class A) (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ORGO 1
— JNJ 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $0.77 (-6.20%) • MKT CAP: $105.4M
roic
17.10%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ORGO VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ORGO | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 17.10% | 25.50% | -8.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -23.21% | 2.97% | -26.18 | JNJ | /fcf-yield <GO> |
| Operating Margin | 7.90% | 34.70% | -26.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 6.60% | 28.50% | -21.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 17.00% | 6.00% | +11.00 | ORGO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.09 | 5.59 | -3.50 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 15.6 | 62.1 | -46.49 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $105.4M | $662.49B | -$662.39B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ORGO REV | JNJ REV | ORGO GROSS % | JNJ GROSS % | ORGO FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $564.2M | $94.19B | — | 67.9% | -$24.5M | $19.70B |
| FY 2024 | $482.0M | $88.82B | 76.0% | 69.1% | $4.2M | $19.84B |
| FY 2023 | $433.1M | $85.16B | — | — | $30.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ORGO // BETA —
JNJ // BETA 1.08